Mosaic ImmunoEngineering Inc. (OTCMKTS:CPMV) Short Interest Up 150.4% in April

Mosaic ImmunoEngineering Inc. (OTCMKTS:CPMV) saw a significant increase in short interest in April. As of April 30th, there was short interest totaling 328 shares, an increase of 150.4% from the April 15th total of 131 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily volume of 713 shares, the days-to-cover ratio is currently 0.5 days.

Mosaic ImmunoEngineering Price Performance

Shares of CPMV opened at $0.69 on Friday. The stock’s 50-day moving average is $0.65 and its two-hundred day moving average is $0.58. The stock has a market cap of $5.03 million, a PE ratio of -6.95 and a beta of -0.68. Mosaic ImmunoEngineering has a 12 month low of $0.25 and a 12 month high of $1.05.

Mosaic ImmunoEngineering (OTCMKTS:CPMV) last issued its quarterly earnings data on Wednesday, April 15th. The company reported ($0.03) EPS for the quarter.

Mosaic ImmunoEngineering Company Profile

Mosaic ImmunoEngineering (OTCMKTS:CPMV) is a development-stage biotechnology company focused on advancing immunotherapies and vaccine candidates through its proprietary nanoparticle platform. The company leverages virus-like particles derived from the cowpea mosaic virus (CPMV) to serve as both antigen carriers and immune stimulators, aiming to enhance the magnitude and durability of immune responses. By engineering these plant-based VLPs to display target antigens or adjuvant properties, Mosaic ImmunoEngineering seeks to create differentiated candidates for oncology indications and infectious disease prevention.

Operating out of the United States, Mosaic ImmunoEngineering is currently in preclinical stages of development.